PRESS RELEASE:

Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines

| From
Epeius Biotechnologies

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.

The advent of pathotropic (disease-seeking) targeting technology first enabled the development of tumor-targeted Rexin-G, which seeks-out, accumulates-in, and selectively delivers a lethal designer gene to tumors that have spread throughout the body (metastatic cancer), halting the progression of disease while improving both survival and quality-of-life. Approved for all solid tumors in the Philippines, Rexin-G has received Orphan Drug and Fast Track status from the U.S. FDA, and is currently moving on to Phase III trials for first-line and second-line indications.

Once the control of tumor growth has been achieved with Rexin-G, the need to extend the treatment intervals and/or clinical remissions led to the development of Reximmune-C, a second tumor-targeted genetic medicine which delivers a pulse of immune-stimulating cytokine directly to the sites of residual or recurrent disease, thereby recruiting the patient's own immune system into the lesions of the residual cancer to invoke a more lasting anti-tumor immune response.

Much like a SWAT (special weapons and tactics) Team that calls an elite police force to the scene of a crime, Reximmune-C acts at the local level, recruiting the body's own professional immune cells, antigen-presenting cells, helper cells, and killer T-cells directly to the locus of the residual cancer, where tumor debris as antigens are abundant.

This provides the patient with an opportunity to mount a beneficial immune response that would further improve clinical outcome. Unlike, previous approaches to personalized cancer vaccination, a simple intravenous infusion of tumor-targeted Reximmune-C marshals the cadre of complex immunological responses of this intrinsic SWAT Team to the place where it is needed most. By reaching beyond the boundaries of medicine to the very crux of metastatic disease, Epeius delivers another vital innovation.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems.

To learn more about our pipeline of proprietary biotechnologies, please visit us at www.epeiusbiotech.com .

* Additional Epeius news and RSS feed:
http://profiles.send2press.com/Epeius_Biotechnologies.shtml .

News Source:
Like, Share, Save this press release:
  TWEET   SHARE   G+   PIN IT   STUMBLE   LinkedIn   Instapaper   Buffer

PERMALINK:
https://www.send2press.com/newswire/2010-03-0316-002.shtml
  LEGAL NOTICE AND TERMS OF USE:  
The content of the above press release was provided by the “news source” (Epeius Biotechnologies Corporation) or authorized agency, who is solely responsible for its accuracy. Send2Press® is the originating wire service for this story and content is Copr. © 2010 Epeius Biotechnologies Corporation with newswire version Copr. © 2010 Send2Press (a service of Neotrope). All trademarks acknowledged.

Rights granted for reproduction by any legitimate news organization. However, if news is cloned/scraped verbatim, then original attribution must be maintained with link back to this page as “original syndication source.” Resale of this content for commercial purposes is prohibited without a license. Reproduction on any site selling a competitive service is also prohibited. Information is believed accurate, as provided by news source or authorized agency, however is not guaranteed, and you assume all risk for use of any information found herein/hereupon. This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
STORY READS for this single page only, as of Sep 27 2016:
[ count retired 8.4.16 ]


back to top
REFERENCES: Epeius Biotechnologies, metastatic cancer treatment, Epeius Biotechnologies Corporation, tumor targeted immunotherapy, metastatic cancer treatment, bio medicine patents, pharma, California tech news, Rexin-G, Reximmune-C, genetic medicine, Orphan Drug and Fast Track status from the US FDA, vaccine technology for cancer, news, press release from Epeius Biotechnologies Corporation, Mar 16, 2010, Drugs and Pharmaceuticals, Health, , San Marino, California, Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines